ATOSSA THERAPEUTICS, INC. 8-K

What Happened

• On February 11, 2026, Atossa Therapeutics, Inc. (ATOS) filed a Form 8-K under Item 7.01 (Regulation FD Disclosure) announcing the issuance of its 2026 Letter to Shareholders via a company press release. The press release and the letter are furnished as Exhibit 99.1 to the Form 8-K. The report was signed by Mark J. Daniel, Chief Financial Officer.

Key Details

• Filing date: February 11, 2026 (Form 8-K, Item 7.01).
• Press release and 2026 Letter to Shareholders attached as Exhibit 99.1.
• Form 9.01 notes the press release date and includes the Inline XBRL cover page file.
• No earnings, quarterly financial results, executive changes, mergers or acquisitions were reported in this filing.

Why It Matters

• The 2026 Letter to Shareholders is the company’s formal communication to investors and may contain strategic updates, progress on programs, or other information relevant to shareholders. Because it was filed under Regulation FD Disclosure, the information was made public to all investors at once. Investors should read the attached press release/letter for any specific material updates and note that this 8-K does not include financial results or management changes.